Overview

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objective of the study is to investigate the relative bioavailability of the final tablet formulation (FF) of BI 10773 in comparison to the tablet formulation 2 (TF2).

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Empagliflozin